A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA)

Jürgen Wolf, Firmin Janssen, Henrik Lublin, Raimo K R Salokangas, Hervé Allain, Enrico Smeraldi, Miguel Bernardo, Helen Millar, Miranda Pans, Christine Adelbrecht, Jim Laughton, Christian Werner, Wolfgang Maier

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To examine the effectiveness of aripiprazole in schizophrenia in a naturalistic setting in 14 European countries. Methods: This multicentre, open-label study of aripiprazole evaluated outpatients with schizophrenia for whom a medication switch was clinically reasonable or antipsychotic initiation was required. Patients (n = 833) were randomized in a 4:1 ratio to aripiprazole (recommended starting dose 15 mg/day, permitted adjustment 10-30 mg/day) (n = 680) or another antipsychotic (safety control [SC] group) (n = 153) for 8 weeks. The control group received an antipsychotic different to their recent pre-study medication. The primary effectiveness measure was the Clinical Global Impression - Improvement (CGI - I) score of aripiprazole-treated patients at Week 8 (last observation carried forward [LOCF]). Patients' and caregivers' medication preference was assessed using the Preference of Medication (POM) questionnaire. The Investigator Assessment Questionnaire (IAQ) was used to record investigators' assessments of their patients' responses to the study antipsychotic. Adverse events (AEs) were recorded. Results: At endpoint (Week 8, LOCF), the mean CGI - I score of 3.16 (95% confidence interval, [CI]: 3.04, 3.28) demonstrated the effectiveness of aripiprazole. At endpoint, 43% of aripiprazole-treated patients showed a response (CGI - I score = 1/2). Aripiprazole was rated as slightly or much better than previous antipsychotic at endpoint by 68% of patients and 65% of caregivers. The mean CGI - I score (Week 8, LOCF) for the SC group was 3.37 (95% CI: 3.14, 3.60). No major differences in the occurrence of AEs were noted between aripiprazole- and SC-treated patients. Limitations: As this is an open-label design, there may have been a bias. Secondly, the study was not powered to show differences between treatment groups and no statistical comparisons were planned. Thirdly, 8 weeks is too short to evaluate long-term effectiveness. Conclusions: Aripiprazole was effective, well tolerated and well accepted by patients and caregivers in this naturalistic study.

Original languageEnglish
Pages (from-to)2313-2323
Number of pages11
JournalCurrent Medical Research and Opinion
Volume23
Issue number10
DOIs
Publication statusPublished - Oct 2007

Keywords

  • Aripiprazole
  • Atypical antipsychotics
  • Effectiveness
  • Naturalistic study
  • Outpatient
  • Schizophrenia

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA)'. Together they form a unique fingerprint.

Cite this